Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience
Article Category: Research Article
Publicado en línea: 19 nov 2021
Páginas: 467 - 473
Recibido: 13 may 2021
Aceptado: 21 sept 2021
DOI: https://doi.org/10.2478/raon-2021-0041
© 2021 Kristin Lang, Melissa Baur, Thomas Held, Rami El Shafie, Julius Moratin, Christian Freudlsperger, Karim Zaoui, Nina Bougatf, Jürgen Hoffmann, Peter K. Plinkert, Jürgen Debus, Sebastian Adeberg, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Background
Surgery is standard of care for oral cavity cancer (OCC). We provide a single-institution experience using definitive radiotherapy (RT) with or without concurrent systemic therapy for primary unresectable OCC.
Patients and methods
We retrospectively examined 49 patients with non-metastatic primary unresectable OCC treated with definitive RT between 2000 and 2019. The majority of patients (63.3%) were treated with definitive chemoradiotherapy while 26.5% were given single-agent cetuximab weekly simultaneous to definitive RT. Five patients were treated with definitive RT alone because of limited disease and no nodal involvement.
Results
Median follow-up was 73 months (range, 6–236 months), median progression free survival (PFS) was 42 months (range, 2–157 months), median local disease-free survival (LDFS) was 44 months (range, 2–157 months) and median overall survival (OS) from the time of RT initiation was 52 months (range, 5–236 months). There were 65.3% locoregional failures, 84.4% local and 15.6% distant metastasis. The majority of patients with local failure presented with American Joint Committee on Cancer (AJCC) Stage III–IV disease (59.2%). The 5-year Kaplan-Meier estimates for OS (III–IV
Conclusions
Definitive RT with or without concurrent systemic agents in patients with unresectable OCC resulted in an eloquent rate of locoregional control and good overall survival rates and is currently the best available treatment option in this patient collective.